NO20044865L - Karbonmonoksid som biomarkor og terapeutisk middel - Google Patents

Karbonmonoksid som biomarkor og terapeutisk middel

Info

Publication number
NO20044865L
NO20044865L NO20044865A NO20044865A NO20044865L NO 20044865 L NO20044865 L NO 20044865L NO 20044865 A NO20044865 A NO 20044865A NO 20044865 A NO20044865 A NO 20044865A NO 20044865 L NO20044865 L NO 20044865L
Authority
NO
Norway
Prior art keywords
disease
lung
cancer
biomarker
therapeutic agent
Prior art date
Application number
NO20044865A
Other languages
English (en)
Norwegian (no)
Inventor
Leo E Otterbein
Augustine M K Choi
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of NO20044865L publication Critical patent/NO20044865L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20044865A 2002-05-09 2004-11-09 Karbonmonoksid som biomarkor og terapeutisk middel NO20044865L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (fr) 2002-05-09 2002-05-09 Monoxyde de carbone servant de biomarqueur et d'agent therapeutique

Publications (1)

Publication Number Publication Date
NO20044865L true NO20044865L (no) 2004-12-07

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044865A NO20044865L (no) 2002-05-09 2004-11-09 Karbonmonoksid som biomarkor og terapeutisk middel

Country Status (13)

Country Link
EP (1) EP1501523A4 (fr)
JP (1) JP2005532314A (fr)
KR (1) KR20040106515A (fr)
CN (1) CN1638781A (fr)
AU (1) AU2002308676B2 (fr)
BR (1) BR0215717A (fr)
CA (1) CA2484770A1 (fr)
EA (1) EA200401478A1 (fr)
MX (1) MXPA04011113A (fr)
NO (1) NO20044865L (fr)
RS (1) RS96904A (fr)
UA (1) UA84402C2 (fr)
WO (1) WO2003094932A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
NZ534912A (en) 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
PL373002A1 (en) 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
CA2481786A1 (fr) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methodes de traitement de l'enterocolite necrosante neonatale
ATE521357T1 (de) * 2002-05-17 2011-09-15 Univ Yale Verfahren zur behandlung von hepatitis
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
AU2007328549A1 (en) * 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
EP3583851A1 (fr) * 2011-01-14 2019-12-25 Children's Hospital Los Angeles Solution de monoxyde de carbone utilisable en vue du traitement d'une maladie, notamment la drépanocytose
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9365419B2 (en) 2011-03-24 2016-06-14 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring alzheimer's disease
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (fr) 2011-07-21 2017-03-22 Alfama, Inc. Molécules libérant du ruthénium-monoxyde de carbone et utilisations de celles-ci
WO2014165732A1 (fr) 2013-04-04 2014-10-09 The Regents Of The University Of California Système et méthode d'utilisation de l'air expiré pour surveiller les états inflammatoires
EP2868348A1 (fr) * 2013-11-04 2015-05-06 Universität Zürich Composés à libération de monoxide de carbone et leurs formulations utiles pour induire la biogenèse mitochondriale et la réparation tissulaire
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
US11576929B2 (en) 2018-06-08 2023-02-14 Sumitomo Seika Chemicals Co., Ltd. Composition for inflammatory gastrointestinal disorders
JP7396598B2 (ja) * 2018-06-08 2023-12-12 住友精化株式会社 皮膚創傷用組成物
WO2020247825A1 (fr) * 2019-06-06 2020-12-10 The General Hospital Corporation Monoxyde de carbone en tant que traitement pour une maladie neurodégénérative
WO2022015986A1 (fr) * 2020-07-16 2022-01-20 Cornell University Méthodes de traitement du cancer métastatique à l'aide de monoxyde de carbone à faible dose
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
DE59710969D1 (de) * 1996-08-27 2003-12-11 Messer Griesheim Gmbh Wasserstoffhaltiges medikament
RU2003131675A (ru) * 2001-03-30 2005-03-10 Сэнгстат Медикал Корпорейшн (Us) Генерирующие моноксид углерода соединения для лечения сосудистых, воспалительных и имунных нарушений

Also Published As

Publication number Publication date
WO2003094932A1 (fr) 2003-11-20
EP1501523A1 (fr) 2005-02-02
JP2005532314A (ja) 2005-10-27
MXPA04011113A (es) 2005-02-14
CA2484770A1 (fr) 2003-11-20
EA200401478A1 (ru) 2005-12-29
RS96904A (en) 2007-02-05
CN1638781A (zh) 2005-07-13
EP1501523A4 (fr) 2006-12-13
KR20040106515A (ko) 2004-12-17
BR0215717A (pt) 2005-02-22
AU2002308676B2 (en) 2009-06-11
UA84402C2 (ru) 2008-10-27
AU2002308676A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
NO20044865L (no) Karbonmonoksid som biomarkor og terapeutisk middel
SE0200356D0 (sv) Novel use
RS51607B (sr) Novi lekovi za tretiranje hroničnog opstruktivnog oboljenja pluća
WO2003070188A3 (fr) Methode de traitement des maladies mediees par la thioredoxine (trx)
HK1123304A1 (en) Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
CA2444578A1 (fr) Utilisation du facteur 2alpha induit par l'hypoxie pour le traitement du syndrome de detresse respiratoire du nouveau-ne et comme cible pour le traitement de l'hypertension pulmonaire
Li et al. TIMP-1 and MMP-9 expressions in COPD patients complicated with spontaneous pneumothorax and their correlations with treatment outcomes
Barton et al. Metalloproteinases and their tissue inhibitors in comparison between different chronic pneumopathies in the horse
EA200700037A1 (ru) Производные n-гидроксиамида и их применение
WO2005086915A3 (fr) Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease
Fitton et al. Impact of secondary pulmonary hypertension on lung transplant outcome
NO20054336L (no) Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
IS2037B (is) Útskiptir beta-díketónar og notkun þeirra
EP1661892A4 (fr) Compos cyclique condens et son utilisation
HK1115132A1 (en) N-hydroxyamide derivatives and use thereof n-
DK1828160T3 (da) Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere
IL180681A0 (en) Pyridine derivatives, their preparation and use
WO2006085226A3 (fr) Blocage d'une inflammation et d'une hypersensibilite des voies respiratoires dans un modele murin d'asthme par le proteine 3 de liaison de facteurs de type insuline (igfbp-3)
San-Huang α-Macroglobulins: a modulator for growth factors
WO2023173036A3 (fr) Inhibiteurs de masp-2 et masp-3, et compositions et méthodes associées pour le traitement de la drépanocytose
ATE328120T1 (de) Bakterienstämme delftia acidovorans mc1-r, ihre herstellung sowie ihre verwendung zur produktion der r-enantiomeren von 2-phenoxypropionsäure- derivaten
UA88785C2 (en) N-hydroxyamide derivatives and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application